DEANGELLA SIMPSON: Open Payments
NPI 1700328135 · SOUTHFIELD, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$592 in 18 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $116 · 2025 $592
Food & beverage: $592
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $179 |
| Alkermes, Inc. | 3 | $173 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $146 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Luye Pharma (USA) Ltd. | 1 | $16 |
Products named: INGREZZA, CAPLYTA, LYBALVI, ARISTADA, UZEDY, ABILIFY MAINTENA, COBENFY, ERZOFRI EXTENDED-RELEASE.
Industry payments across MI — which companies pay providers there.
